ReviewInternational journal of molecular sciences2023
Inflammatory Bowel Diseases and Gut Microbiota.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Association between inflammatory bowel disease and the risk of liver cancer: a systematic review and meta-analysis.Clinical and experimental medicine · 2025Pooled it
- Efficacy of different psychological interventions for the treatment of inflammatory bowel disease: a systematic review and network meta-analysis.Frontiers in medicine · 2025Pooled it
- Gut microbiota metabolites in the immunoregulation of enteritis: research progress.Frontiers in immunology · 2025Pooled it
- Debate on the relationship betweenFrontiers in microbiology · 2024Pooled it
- Safety and Tolerability of Xanthohumol in Adults With Crohn's Disease: Results of a Triple-Masked, Randomized, Placebo-Controlled Phase 2 Trial.Molecular nutrition & food research · 2026Trial
- The gut microbiota-tryptophan metabolism-immune axis in inflammatory bowel disease: Mechanisms and therapeutic prospects.Human vaccines & immunotherapeutics · 2026Review
- Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy.Alimentary pharmacology & therapeutics · 2026Review
- Probiotics in Autoimmune Disease: Strain-specific Mechanisms and Therapeutic Perspectives.Clinical reviews in allergy & immunology · 2026Review
- A microbial PPARadigm for gut protection.Nature microbiology · 2026Article
- Revisiting the Oral-Gut Axis: Microbial Symbiosis, Dysbiosis, and Bidirectional Links Between Periodontitis and Inflammatory Bowel Disease.Microorganisms · 2026Review
- Marine Collagen Peptide Fraction fromFoods (Basel, Switzerland) · 2026Article
- In vivo systemic toxicity assessment of Bacillus safensis NMCC-189: a probiotic strain evaluated via short-term tolerability and 28-day repeated-dose (OECD 407) study in Balb/c mice.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Metagenomic profiling of gut microbiome in post-cholecystectomy patients with diarrhea: a nested case-control study.BMC microbiology · 2026Article
- Pediatric health: mechanistic insights into inflammatory diseases and emerging therapeutic pathway-targeted approaches.Translational pediatrics · 2026Review
- The Toxicity of Tire Wear Particles and Their Leachates on Digestion and Gut Microbiota ofToxics · 2026Article
- ST8Sia6-dependent glycosylation restrains gut inflammation and pathogenic TCell reports · 2026Article
- Environmentally mediated interactions predict community assembly and invasion success in a gut microbiota synthetic community.mSystems · 2026Article
- Article
- Roles of gut and oral microbiota in methamphetamine-induced multi-organ toxicity.Cell biology and toxicology · 2026Review
- Dysbiosis of fecal virome in pediatric Crohn's disease and its dynamic changes during infliximab therapy.mSystems · 2026Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Inflammatory bowel disease (IBD) is an inflammatory disease of the gastrointestinal tract, the incidence of which has rapidly increased worldwide, especially in developing and Western countries. Recent research has suggested that genetic factors, the environment, microbiota, and immune responses are involved in the pathogenesis; however, the underlying causes of IBD are unclear. Recently, gut microbiota dysbiosis, especially a decrease in the abundance and diversity of specific genera, has been suggested as a trigger for IBD-initiating events. Improving the gut microbiota and identifying the specific bacterial species in IBD are essential for understanding the pathogenesis and treatment of IBD and autoimmune diseases. Here, we review the different aspects of the role played by gut microbiota in the pathogenesis of IBD and provide a theoretical basis for modulating gut microbiota through probiotics, fecal microbiota transplantation, and microbial metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.